Dulaglutide Retatrutide KLOW80 TB500 GHK-CU China Fast Delivery High purity Pep..tide Factory 99%..
TDS 59 Inquiries
89030-95-5
Pharmaceutical Grade
99%
Hong Kong
customizable
10vials/box
2027-12-31
Tirzepatide,Retatrutide,Survodutide,GHK-CU,GLOW,KLOW
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCopper Tripeptide is a tripeptide molecule rich in copper ions. Its sequence is GHK and it is widely present in human blood, saliva and urine. With age, the concentration of GHK gradually decreases, which is related to the decline of organ regeneration ability. Copper Tripeptide has strong antioxidant capacity, neutralizes free radicals, protects the skin from environmental damage, and with its unique copper ion affinity, it plays a role in promoting wound healing and activating skin regeneration.Certificates
-
TDS
Basic Info-
Product Name:
Copper tripeptide
Other Name:[N2-(N-Glycyl-L-histidyl)-L-lysinato(2-)]copper;Ghk-Cu/AHK-CU;Copper tripeptide (GHK-Cu);Prezatide copper,[N2-(N-Glycyl-L-histidyl)-L-lysinato(2-)]copper;tripeptide/GHK-Cu;Copper peptide, GHK-Cu, Copper tripeptide-1;GHK Copper;GHK.CU.HAC
CAS No.:89030-95-5
Molecular Formula:C14H21CuN6O4
InChIKeys:DDNUEECOCUBKBT-MIIMWFGWNA-L
Molecular Weight:400.91
Exact Mass:402.10800
EC Number:1308068-626-2
Color/Form:Light blue to blue
Categories:
Characteristics-
PSA:
186.03000
XLogP3:1.04530
Critical Temperature & Pressure:under inert gas (nitrogen or Argon) at 2–8 °C
Research-
Class:
GLP-1 receptor agonist (GLP-1 analog fused to human IgG4-Fc, long-acting)
Status:FDA-approved (Trulicity 2014)
Mechanism:A long-acting GLP-1 receptor agonist consisting of a modified human GLP-1 molecule (7-37) covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. The Fc fusion extends the half-life to ~5 days, allowing once-weekly dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying.
Activity note:Dulaglutide is a dual-agonist with GLP-1R activation. The exact EC50 is proprietary; functional potency is comparable to other long-acting GLP-1R agonists.
Source:DrugBank: DB09095; PubChem CID 16135271.
Clinical Development:FDA:Trulicity (approved 2014-09-18)
References-
DrugBank:PubChem:Disclaimer:
Dulaglutide is FDA-approved as a prescription medicine (Trulicity) for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Survodutide,GHK-CU,GLOW,KLOW
-
Location:
Building 1, Floor 2, No. 96 Banhe Road, Huangpu District, Guangzhou City, Room 2164
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
12
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA
-
-
Inquiry History59 Inquiries
Country Product Purchase Quantity Date Posted
Malaysia
Peptide GHK-Cu Copper Tripeptide-1 Powder CAS 89030-95-5
10 MG Apr 24, 2025
United States
GhkCu
5 G Aug 5, 2026
United States
ghkcu
10 MG Jul 29, 2026
Philippines
Ghkcu
20 Jul 28, 2026
United States
Ghk cu
12 Jul 8, 2026
United States
ghk cu
1 G Jun 12, 2026
United States
Ghk cu
5 MT Jun 11, 2026
Netherlands
ghk-cu
50 MG May 19, 2026
United Kingdom
ghk cu
500 MT Apr 26, 2026
United States
GKHcu
1 G Apr 24, 2026
Canada
ghk cu
1 G Mar 30, 2026
United States
Ghk cu
1 KG Mar 18, 2026
Australia
Ghk Cu
1 KG Feb 2, 2026
Canada
GHK-CU
50 MG Jan 26, 2026
United States
Ghk cu copper peptide
500 MG Dec 8, 2025
United States
GHK-CU Raw
1 G Nov 12, 2025
Latvia
GHK-Cu tripeptide
10 G Aug 4, 2025
Israel
ghk-cu
5 20' Fcl Feb 28, 2024
Hungary
Copper Tripeptide GHK-Cu AHK-Cu 98%
100 G Jan 24, 2024
Australia
Copper Tripeptide-1
1 KG Jan 9, 2024 Post an enquiry for this product
